semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 3.0-10.0,  Growth Hormone Deficiency Have an established diagnosis of PGHD as determined by standard diagnostic criteria. Eligible subjects must be naïve-to-treatment and be prepubertal Morning cortisol ≥ 8 mcg/dL or stimulated cortisol ≥ 16 µg/dL At Screening, be ≥ 3.0 years and < 10.0 years for girls and < 11.0 years for boys Have HT-SDS < -2.0 Have a bone age < 9.0 years for girls and < 10.0 years for boys Have prepubertal status as evidenced by Tanner Stage I breast development in girls and testicular volume < 4.0 mL in boys In girls, have genetic testing results to rule out Turner syndrome. If SHOX genetic testing results are available, they need to be negative Have normal thyroid function. Subjects diagnosed with hypothyroidism must have documented successful treatment for at least 30 days prior to Day 1  Any medical or genetic condition which, in the opinion of the Investigator or Medical Monitor (MM), can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment. (Examples: diabetes, named syndromes) A medical or genetic condition that, in the opinion of the Investigator and/or MM, adds unwarranted risk to use of LUM-201 or rhGH Use of any medication that, in the opinion of the Investigator and/or MM, can independently cause short stature or limit the response to exogenous growth factors (Example: glucocorticoids) Evidence or history of an intracranial mass (e.g., pituitary tumor, craniopharyngioma) Suspicion of absent pituitary function as evidenced by a maximal stimulated GH ≤ 3 ng/mL on two prior standard of care GH stimulation tests, or pituitary deficiencies beyond GH and thyroid function Malnutrition as evidenced by medical history or a body weight < 5th percentile for current height BMI > 95th percentile Gestational age-adjusted birth weight < 5th percentile (small for gestational age) History of spinal, cranial, or total body irradiation A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and/or use of medications to treat ADHD
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Huntington Disease Key Patient successfully completed the Phase 1b/2a study with WVE-120101, WVE-HDSNP1-001. Key  Received an investigational drug other than WVE-120101, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer Inability to undergo brain MRI (with or without sedation) Clinically significant medical finding on the physical examination other than HD that, in the judgment of the Investigator, will make the patient unsuitable for participation in and/or completion of the study procedures
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Recurrent Acute Myeloid Leukemia Documented informed consent of the participant and/or legally authorized representative Age: >= 18 years on the day of signing informed consent Eastern Cooperative Oncology Group (ECOG) =< 2 Patients with histologically confirmed acute myeloid leukemia (AML), according to World Health Organization (WHO) with relapsed disease after allogeneic hematopoietic cell transplantation (alloHCT) Patients with non-central nervous system (CNS) extramedullary disease may be included if they also have marrow disease Patients with acute promyelocytic leukemia (APL) will not be eligible Fully recovered from the acute toxic effects (except alopecia) to =< grade 1 of prior anti-cancer therapy Total bilirubin =< 2 x ULN (unless has Gilbert's disease) (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated in the study calendar) Aspartate aminotransferase (AST)=< 2 x ULN (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated in the study calendar) Alanine aminotransferase (ALT) =< 2 x ULN (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated in the study calendar) (to be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated in the study calendar)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Herpes Simplex Virus Infection Five-months-old infants or younger  Six-months-old infants or older
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thrombotic Microangiopathies Hemolytic Uremic Syndrome, Atypical Hemolytic-Uremic Syndrome Males or females at least 18 years of age Have acute kidney injury, defined as estimated GFR <45 mL/min/1.73m2 Have documented TMA either on peripheral blood, defined as Coombs negative microangiopathic hemolytic anemia (hematocrit <30%, hemoglobin <6.5 mmol/L [<10 g/dL], lactate dehydrogenase >500 U/L, and either schistocytes on peripheral blood smear or undetectable haptoglobin), and platelets <150,000 per µL, or kidney biopsy Have primary atypical HUS or a coexisting condition linked to complement dysregulation Hypertensive emergency, defined as SBP/DBP of >180/120 mmHg and impending organ damage secondary to hypertension (at least one of the following: neurologic disease, hypertensive retinopathy grade III and/or IV, left ventricular hypertrophy); OR Pregnancy, including 12 weeks postpartum; OR Kidney donor recipient; OR Systemic auto-immune disease associated with TMA, including systemic sclerosis, systemic lupus erythematosus, anti-phospholipid syndrome Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures  Have secondary causes of hypertensive emergency, including renovascular hypertension, Cushing syndrome, aldosteronism, pheochromocytoma, thyroid disease Have a nephropathy not related to thrombosis on kidney biopsy Have deficiency, defined as activity <10% Have a positive stool culture for Shiga toxin producing bacteria Have positive serologic test for viral infections, including HIV and CMV Have a history of malignant disease, excluding non-melanoma skin cancer Have a history of bone marrow or solid organ transplantation, excluding kidney transplantation Received at least one of the following agents: chemotherapeutics, sirolimus, anti-VEGF agents Have a history of recent past exposure to illicit drug(s)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.5-0.583,  Down Syndrome Infants were confirmed to have Down syndrome of non disjunction genotype Age was around 6 month, at time of recruitment Legal guardians accepted to participate in the study and sign the informed consent  Patients having uncontrolled hypothyroidism Patients with brain malformations other than the expected in infant with Down syndrome Patients with hearing and / or vision impairments severe congenital heart disease Patients having contraindications for the use of Cerebrolysin
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Growth Hormone Deficiency Idiopathic Short Stature Turner Syndrome Small for Gestational Age Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA) Children who has official height record at least 6 months prior  Children with Epiphyseal closure
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 4.0-9.0,  Growth Hormone Deficiency Have a chronological age > 4.0 years and < 8.0 years for girls and < 10.0 years for boys Have a minimum body weight of 17 kg at the time of screening Have a bone age examination at screening or within the 6 months prior to screening that, in the interpretation of the PI, is delayed with respect to chronological age Have a HT-SDS < -2.0 Have a maximal GH response < 10 ng/mL from at least one prior GH stimulation test within the past 6 months Have prepubertal status as evidenced by Tanner Stage I breast development in girls and testicular volume < 4.0 mL in boys Have height minus arm span difference < 4.5 cm In girls, have genetic testing results to rule out Turner syndrome. If SHOX genetic testing results are available, they need to be negative Have normal thyroid function. Subjects diagnosed with hypothyroidism must have documented successful treatment for at least 30 days prior to the Baseline visit  Any medical or genetic condition which, in the opinion of the PI or Medical Monitor (MM), can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment (e.g., diabetes) A medical or genetic condition that, in the opinion of the PI and/or MM, adds unwarranted risk to use of LUM-201 (e.g., scoliosis) Use of any medication that, in the opinion of the PI and/or MM, can independently cause short stature or limit the response to exogenous growth factors (e.g., glucocorticoids) Evidence or history of an intracranial mass (e.g., pituitary tumor, craniopharyngioma) Prior treatment with growth factors including, but not limited to, GH, IGF-1, and GH secretagogues. (These may be used for limited times as a diagnostic test.) Suspicion of absence of pituitary function as evidenced by a maximal stimulated GH ≤ 3 ng/mL or pituitary hormone deficiencies beyond GH and thyroid function Gestational age-adjusted birth weight < 5th percentile (small for gestational age) At birth, gestational age < 36.0 weeks Participation in any trial of investigational drug(s) within the prior 6 months History of spinal or total body irradiation
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  CTNNB1 Gene Mutation Patients with a diagnosed mutation in the CTNNB1 gene Patients whose parents/caregivers were informed about the aims of the study and have signed the Informed consent form  Patients who do not have a diagnosed mutation in the CTTNB1 gene Patients whose caregivers have not signed the Informed consent form
Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-3.0,  Hepatitis B Hepatitis, Viral, Human Liver Diseases Boy and girl infants, birth to 3 years, born to mothers who were hepatitis B surface antigen carriers
Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  HIV Infections HIV Seronegativity A child may be eligible for this study if he/she Is 0 years old Is HIV-negative and is born to an HIV-negative mother Is healthy (no serious infection or disease) Has signed informed consent of a parent or legal guardian if under 18  A child will not be eligible for this study if he/she Is pregnant or breast-feeding Has already completed this study once before Is taking prescription medications other than prescription vitamins
Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Healthy Strabismus Participants must have a gestational age at birth between 36-42 weeks and birth weight greater than or equal to 2500 gms. Participants must have normal growth and development as assessed by general pediatric examination and growth charts, obtained historically from family and/or pediatrician. Participants must have a normal visual system by ophthalmic examination. Participants must be between the post-conceptual ages of 40 weeks and 70 weeks of age inclusive. Participants must be able to undergo a complete opthalmic evaluation. Participants must be able to undergo standard eye movement recording. Participants must not have any eye diseases. Participants must not have any neurologic disease, developmental delay, congenital genetic syndromes, congenital organ malformations, malformation syndromes or metabolic diseases. Participants must not be on any systemic or ocular medications
Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Dwarfism Growth Disorder Patients with extreme short stature will qualify for under this protocol if they meet the following Age 9 through 15.99 years at the start of treatment. Tanner II-V pubertal development. Height at least 2.25 S.D. below the median for chronologic age at the time of pubertal onset, or a predicted adult height at least 2.25 S.D. below median adult height. The height criterion must be met before study entry, but not necessarily on the actual date the patient starts to take the protocol injections because advancing puberty may cause an increase in height velocity that temporarily increases height standard deviation score. Unfused carpal and phalangeal epiphyses by bone age x-ray
Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Neoplasms Lymphoma Neoplasm Metastasis Testicular Neoplasms A history of pathologically documented (clinical documentation may be acceptable at relapse): Breast cancer: metastatic or locally advanced (Stage III/IV) with stable minimal (less than or equal to 2 cm) residual disease after 2 cycles of appropriate combination chemotherapy may start BMT. Non-Hodgkin's lymphomas: all stages of relapsed or induction failure (FSC, FM, FL, DSC, DL, DM, DIDL, IBL, LBL, SNC) after appropriate chemotherapy. Hodgkin's lymphomas: all stages of chemotherapy induction failures, first relapse less than or equal to 1 year from chemotherapy induced remission, first relapse greater than 1 year from chemotherapy induced remission if there is extranodal involvement at relapse, greater than or equal to 2 relapses (one may be after radiation) following appropriate combination chemotherapy, or relapse at any time from radiation therapy with stage IIB, IIIB, IV A/B. Testicular cancer: all stages of relapsed or induction failure following appropriate combination chemotherapy. No evidence of central nervous system cancer. Patients must be between 18 and 65 years old. Normal cardiac function: no history of angina pectoris, myocardial infarction, congestive heart failure or ejection fraction less than 40 percent. Creatinine clearance greater than or equal to 45 cc/min/m(2), bilirubin less than or equal to 1.5, SGOT less than or equal to 2x normal, and normal PT, PTT and calcium. Negative HIV serology and hepatitis B surface antigen. Adequate pulmonary function (PFTs are only obtained in patients with clinical evidence of pulmonary dysfunction): DLCO greater than 50 percent, compensated for Hgb, FEV 1 greater than 55 percent and PO2 greater than 60. Negative bilateral bone marrow biopsies prior to bone marrow harvest. No evidence of metastatic disease to the pelvis on plain film or bone scan. Karnofsky performance status greater than or equal to 70 and a life expectancy greater than or equal to 60 days. No evidence of pregnancy or risk of pregnancy at the time of transplantation in women. Ability to give informed consent. Good psychiatric and medical risk